H.C. Wainwright lowered the firm’s price target on TuHURA Biosciences (HURA) to $12 from $13 and keeps a Buy rating on the shares following the Q4 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Announces Acquisition of Kineta, Inc.
- TuHURA Biosciences Expands Board with New Appointment
- TuHURA Biosciences appoints Craig Tendler to board of directors
- Dollar General downgraded, Oracle upgraded: Wall Street’s top analyst calls
- TuHURA Biosciences initiated with a Buy at H.C. Wainwright